Jenkins R T, Ramage J K, Jones D B, Collins S M, Goodacre R L, Hunt R H
Department of Pathology, McMaster University Health Sciences Centre, Hamilton, Ontario.
Clin Invest Med. 1988 Apr;11(2):151-5.
51Cr-EDTA was administered both orally and per rectum via a catheter to controls and to patients with inflammatory bowel disease. The patients were divided into two groups, either with active inflammation of the small bowel or with active inflammation of the colon. Fifteen patients with Crohn's disease of the small bowel and 19 patients with either Crohn's disease of the colon or ulcerative colitis were investigated. After oral administration of the probe, controls showed a median excretion of 1.17%/24 h of the dose compared to 3.47%/24 h by patients with small bowel disease and 6.07%/24 h by patients with colonic disease. After rectal administration, controls showed a median excretion of 0.74%/24 h of the dose compared to 0.93%/24 h by patients with small bowel disease and 5.73%/24 h by patients with colonic disease. The rectal test differentiated small bowel disease from colonic disease with an accuracy of 85%. The results confirmed the inflamed colon as a site of increased intestinal permeation.
通过导管经口和直肠向对照组以及炎症性肠病患者施用51Cr-乙二胺四乙酸。患者被分为两组，一组为小肠有活动性炎症，另一组为结肠有活动性炎症。对15例小肠克罗恩病患者以及19例结肠克罗恩病或溃疡性结肠炎患者进行了研究。口服探针后，对照组的剂量中位排泄率为1.17%/24小时，小肠疾病患者为3.47%/24小时，结肠疾病患者为6.07%/24小时。直肠给药后，对照组的剂量中位排泄率为0.74%/24小时，小肠疾病患者为0.93%/24小时，结肠疾病患者为5.73%/24小时。直肠检测区分小肠疾病和结肠疾病的准确率为85%。结果证实发炎的结肠是肠道通透性增加的部位。
Zotero 插件